In the final days of the Biden Administration, the United States Food and Drug Administration (FDA) finalized the guidance on ...

In the final days of the Biden Administration, the United States Food and Drug Administration (FDA) finalized the guidance on… ...

OIG’s Office of Audit Services released its latest report on providers’ compliance with the Hospital Price Rule (the HPT Rule ...

In the final days of the Biden administration the Drug Enforcement Administration (DEA) has issued new regulations on who can ...

The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...

President Donald Trump's lineup of nominees for top healthcare positions is set to introduce significant reforms aimed at ...

We’ve previously written about state prescription drug affordability review boards (PDABs) that have been instituted around ...

Policy & Medicine offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Since its inception in 2008, Policy & Medicine has become one of the ...

According to a recent study published in Health Affairs, telemedicine offerings vary widely based on unique circumstances and ...

The United States Court of Appeals for the Second Circuit recently revived a whistleblower lawsuit against Novartis,  marking ...

We’ve previously written about state prescription drug affordability review boards (PDABs) that have been instituted around the country, often with the intent to review higher-cost prescription drugs ...

In a compelling episode of "," Dr. John Marshall engages in a profound dialogue with Julie Fleshman, a vanguard in the realm ...